Deep Sail Capital, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The fund returned 5.8% net of fees in the third quarter, ...

ClearPoint Neuro’s updated fair value estimate sits at US$25.00, compared with the prior US$24.00, putting a fresh spotlight on how analysts are recalibrating expectations. This shift reflects a mix ...

ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of ...

ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of ...

ClearPoint Neuro reported total operating expenses of $11.3 million in the quarter. The company ended the period with $12.4 million in cash and cash equivalents. “Our 2025 fiscal year is off to a ...

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration FTD is a devastating form of early-onset dementia that ...

The average one-year price target for ClearPoint Neuro (NasdaqCM:CLPT) has been revised to $25.50 / share. This is a decrease ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday. Shares of ...